Celldex Therapeutics | CLDX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 538M 2026-03
Agenus USD -221.22M 241.03M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Celldex Therapeutics USD 456.23M 368.95M 2026-03
Glaxosmithkline GBP 9.17B 1.4B 2025-12
Nektar Therapeutics USD 40.9M 44.19M 2025-12
Northwest Biotherapeutics USD -108.65M 8.26M 2025-09
Pfizer USD 90.1B 77.19B 2026-03
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Roche Holding CHF 21.01B 10.84B 2025-12